ERS COPD Research Award 2008 sponsored by Boehringer Ingelheim

Boehringer IngelheimThe European Respiratory Society (ERS) has announced that Dr Esther Barreiro, Municipal Institute of Medical Investigation/Hospital del Mar in Barcelona, Spain is this year's winner of the Society's annual award for research in the field of Chronic Obstructive Pulmonary Disease (COPD).

The ERS COPD Research Award recognises the work of young European ERS member active in pulmonology research and has been awarded for the eighth time this year. It is sponsored by Boehringer Ingelheim and consists of one sponsorship totalling 50,000 Euros to be used for scientific research projects in the field of COPD.

This year, the prize of 50,000 Euros goes to Esther Barreiro for her study of the specific role of oxidative stress in the respiratory and peripheral muscle dysfunction of COPD patients. Her research of these pathophysiological mechanisms provides the basis for future therapeutic strategies aimed at restoring muscle mass and function. Elucidation of the precise mechanisms will improve the quality of life and survival of COPD patients whereby oxidants modulate muscle proteolysis and apoptosis in the COPD muscle dysfunction appears to be of viral importance given its potential therapeutic implications in these patients.

Dr Barreiro obtained her MD degree at Universitat de Barcelona and became specialized in Respiratory Medicine after finishing the official Spanish residency training period. She began her research career in 1997 at IMIM-Hospital del Mar in Barcelona. She received her Master of Science degree from McGill University, Montreal, Canada, and one year later her PhD degree at Universitat Pompeu Fabra in Barcelona. In October 2001, she joined the IMIM-Hospital del Mar with the aim of investigating the specific roles played by oxidative stress and inflammation in the muscle dysfunction of patients with COPD. In 2004, she also became an Associate Professor of the Experimental Sciences and Health Department at Universitat Pompeu Fabra in Barcelona.

"The ERS is delighted to receive so many applications at such a high standard this year and wishes to thank all applicants for their contributions. In particular, we congratulate Esther Barreiro for her excellent work and extend our thanks to Boehringer Ingelheim, a leader in the research and treatment of COPD, for making this award possible," said Leonardo Fabbri, ERS President. "I would also like to take this opportunity to invite members to submit entries for next year's award."

European members of the ERS up to age 45 are eligible to apply for the award. The official online application form can be found on the ERS website, http://www.ersnet.org. The deadline for applications is 26 February 2009. Selection of the successful candidates will be made by the Scientific Committee of the ERS.

The European Respiratory Society
Founded in 1990, the European Respiratory Society (ERS) is a not-for-profit, international medical organisation with almost 9,000 members - scientists, doctors and allied health professionals, coming from over 100 countries. The Society's mission is to alleviate suffering from respiratory disease and to promote lung health through research, knowledge sharing, medical and public education, and working with patient organisations.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

Most Popular Now

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...